Abiraterone/prednisone plus ADT for early prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests adding abiraterone (a hormone therapy pill) and prednisone to standard hormone therapy (ADT) for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. The goal is to see if this combination works better than ADT alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of prostate cancer that has not been treated yet.
- A special PET scan (PSMA-PET) shows a small lymph node with cancer in the pelvis (less than 1 cm).
- You are able to swallow pills.
- You are 30 years or older.
- You have no other serious health problems (like unstable heart disease, uncontrolled diabetes, or recent blood clots).
- You do not have cancer that has spread outside the pelvis (like to bones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This study is comparing two drugs, abiraterone and darolutamide, to see how well they work for advanced prostate cancer. You might join if your cancer has spread and your doctor agrees these treatments could help.
This trial studies giving radiation and hormone-related treatment before surgery (to remove the prostate) for men whose prostate cancer has spread to a small number of sites. It may help control the cancer earlier and improve outcomes by treating both the prostate and the limited metastases.
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.